Cytokine Signalling Forum

Laura Coates takes you through our top picks from the selection of psoriatic arthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

Laura Coates takes you through our top picks from the selection of axial spondyloarthritis abstracts at EULAR 2022 today (Wednesday 1 June). Today's abstracts have been divided into three podcasts covering RA, PsA, and axSpA. They're all available right here on the CSF podcast channel, so make sure you don't miss them!

EULAR 2022 Preview Podcast by The CSF

Join Prof Iain McInnes as he reviews two interesting papers published in May 2022! The first – from Bartlett et al – looks at the impact of tofacitinib on fatigue, sleep and HRQoL in patients with RA. While the second assesses the impact of JAKi or abatacept on RA-interstitial lung disease. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Peter Taylor, from the University of Oxford in the UK. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Peter Taylor discusses pain control in early RA treated with baricitinib monotherapy.

Prof Iain McInnes reviews three papers this month!. The first – from Taylor et al – looks at pain control in early RA treated with baricitinib, the second investigates the immunogenicity of pneumococcal vaccination in patients with RA receiving upadacitinib and MTX, and the third paper is a perspective on regulatory changes in the wake of the ORAL SURVEILLANCE results. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Rüdiger Müller, Rheumazentrum Ostschweiz, Switzerland. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Rüdiger Müller discusses his paper on the impact of switching tofacitinib dose in patients with RA.

Discussing Rheumatology: March 2022 by The CSF

Professor Roy Fleischmann, from the University of Texas Southwestern Medical Centre in Dallas. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleischmann discusses the long-term safety and efficacy of upadacitinib or adalimumab in patients with RA.

Prof Iain McInnes reviews two papers this month, both on tofacitinib. The first looks at CV outcomes from the STAR-RA study, the second is a post-hoc analysis of ORAL Sequel looking into tofacitinib dose switching. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

ACR1540 Ana Rita Cruz - Machado by The CSF

ACR1087 Omar Alsaed by The CSF

Professor Roy Fleishmann, clinical professor of medicine at the University of Texas Southwestern Medical Center. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Roy Fleishmann discusses the ORAL Surveillance study into CV and cancer risks with tofacitinib in patients with RA.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the clinical management of HZ in patients with RA or PsA receiving tofacitinib.

Prof Iain McInnes reviews two papers this month, and discusses the risk of herpes zoster (HZ) events in patients with RA treated with tofacitinib, as well as interstitial lung disease (ILD), an extra-articular manifestation of RA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Prof Iain McInnes reviews two papers this month, and discusses exposure-adjusted incidence rates of TEAEs and AESIs with filgotinib, as well as the efficacy and safety of tofacitinib in pJIA. Keep up to date with the latest in arthritis and cytokine signalling with Prof Iain McInnes. Everything discussed is available in a more detailed slide format in the publications section at cytokinesignalling.com.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the safety of filgotinib in patients with RA.

Professor Kevin Winthrop, Professor of Medicine at Oregon Health & Science University. Join Professor Peter Nash as he interviews authors of recent notable papers in rheumatology. In this edition, Professor Kevin Withrop discusses his paper on the incidence and risk of herpes zoster in patients with RA receiving upadacitinib.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.

Gain insight into the latest research presented at ACR 2021. Experts review their congress posters and presentations on cytokine signalling and JAK inhibitors.